IN6 ADVANCES IN CYTOTOXIC AND OTHER TARGETED THERAPY OUT OF HER2, ER AND TRIPLE NEGATIVE METASTATIC BREAST CANCERS
نویسندگان
چکیده
منابع مشابه
Targeted Therapy of HER2-Negative Breast Cancer.
Personalized and targeted treatments are the most discussed topics in oncology. However, how much personalized medicine is standard of care nowadays and how much is part of our hope for a better future? So far, only a few targeted therapies are available in daily practice for the treatment of human epidermal growth factor receptor 2 (HER2)-negative breast cancer. And even for these few targeted...
متن کاملClinicopathological Features of Non-metastatic Triple Negative Breast Cancer
Background: Triple negative breast cancer (TNBC) is reported to be associated with a high risk of recurrence, poor overall survival (OS), and disease-free survival (DFS) rates. This study evaluated the clincopathological features and survival of non-metastatic TNBC women in the capital of Iran compared with other areas of the world. Methods: In a retrospective study, 119 women with TNBC based ...
متن کاملStandard therapy of HER2-positive and triple negative metastatic breast cancer – present and future
TREATMENT OF HER2-POSITIVE METASTATIC BREAST CANCER The treatment of HER2-positive metastatic breast cancer (MBC) has been improved. The HER family consists of four transmembrane receptors that mediate in a complex network of signaling pathways (1). HER1, HER2, and HER3 are all implicated in the development and progression of cancer (2, 3). The HER1 and HER2 receptors are perhaps the best known...
متن کاملTargeted therapies for ER+/HER2- metastatic breast cancer
The majority of breast cancers present with estrogen receptor (ER)-positive and human epidermal growth factor receptor (HER2)-negative features and might benefit from endocrine therapy. Although endocrine therapy has notably evolved during the last decades, the invariable appearance of endocrine resistance, either primary or secondary, remains an important issue in this type of tumor. The impro...
متن کاملRecent advances in managing triple-negative breast cancers
Triple-negative breast cancer (TNBC) has been recently recognized as an important subgroup of breast cancer with a distinct outcome and therapeutic approach compared with other breast cancer subgroups. Because TNBC is defined by the absence of a target (either hormone receptors or HER-2), conventional cytotoxic therapy is still the mainstay of treatment. This report focuses on the current state...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Breast
سال: 2013
ISSN: 0960-9776
DOI: 10.1016/s0960-9776(13)70021-3